{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:02:45Z","timestamp":1782925365751,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neuropharm.2022.109310","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T19:40:18Z","timestamp":1667072418000},"page":"109310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8175-0553","authenticated-orcid":false,"given":"Melissa","family":"Barker-Haliski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Steve","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109310_bib1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00001756-200506210-00007","article-title":"24S-hydroxycholesterol induces inflammatory gene expression in primary human neural cells","volume":"16","author":"Alexandrov","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2022.109310_bib2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1528-1157.1995.tb01005.x","article-title":"Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984","volume":"36","author":"Annegers","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","article-title":"The novel object recognition memory: neurobiology, test procedure, and its modifications","volume":"13","author":"Antunes","year":"2012","journal-title":"Cognit. Process."},{"key":"10.1016\/j.neuropharm.2022.109310_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1474-4422(14)70114-0","article-title":"Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa","volume":"13","author":"Ba-Diop","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib5","series-title":"Development of an Antiepileptogenesis Drug Screening Platform: Effects of Everolimus and Phenobarbital","author":"Barker-Haliski","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109310_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.114.222513","article-title":"Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model","volume":"353","author":"Barker-Haliski","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109310_bib7","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/epi.13577","article-title":"Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy","volume":"57","author":"Barker-Haliski","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2022.109310_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy","volume":"58","author":"Barker-Haliski","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/epi.13476","article-title":"Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice","volume":"57","author":"Barker-Haliski","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eplepsyres.2003.08.001","article-title":"Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models","volume":"56","author":"Barton","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2022.109310_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2016.02.011","article-title":"Brain inflammation, neurodegeneration and seizure development following picornavirus infection markedly differ among virus and mouse strains and substrains","volume":"279","author":"Broer","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib12","article-title":"Etiology of epilepsy in Ecuador","volume":"42","author":"Carpio","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2014.08.002","article-title":"Assessing rodent hippocampal involvement in the novel object recognition task. A review","volume":"285","author":"Cohen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109310_bib14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ana.24795","article-title":"Diagnostic criteria for neurocysticercosis","volume":"80","author":"Del Brutto","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/epi4.12399","article-title":"EEG findings in acutely ill patients investigated for SARS-CoV-2\/COVID-19: a small case series preliminary report","volume":"5","author":"Galanopoulou","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neuropharm.2022.109310_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbr.2014.10.025","article-title":"Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents","volume":"285","author":"Grayson","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109310_bib17","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2022.109310_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nlm.2004.03.005","article-title":"On the delay-dependent involvement of the hippocampus in object recognition memory","volume":"82","author":"Hammond","year":"2004","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.109310_bib20","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/epi.17062","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice","volume":"62","author":"Hawkins","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib21","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2009.02390.x","article-title":"Innate but not adaptive immune responses contribute to behavioral seizures following viral infection","volume":"51","author":"Kirkman","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib23","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1021\/acs.jmedchem.1c00864","article-title":"Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H)","volume":"64","author":"Koike","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109310_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.nut.2016.01.009","article-title":"The effects of diet on the severity of central nervous system disease: one part of lab-to-lab variability","volume":"32","author":"Libbey","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.neuropharm.2022.109310_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.expneurol.2016.04.010","article-title":"NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection","volume":"280","author":"Libbey","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib26","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1528-1167.2008.01535.x","article-title":"Seizures following picornavirus infection","volume":"49","author":"Libbey","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.expneurol.2019.04.010","article-title":"Genetic and pharmacological manipulation of glial glutamate transporters does not alter infection-induced seizure activity","volume":"318","author":"Loewen","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/epi4.12550","article-title":"Screening of prototype antiseizure and anti-inflammatory compounds in the Theiler's murine encephalomyelitis virus model of epilepsy","volume":"7","author":"Metcalf","year":"2022","journal-title":"Epilepsia Open"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109310_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2008.01751.x","article-title":"Viral encephalitis and epilepsy","volume":"49","author":"Misra","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109310_bib31","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/epi.17232","article-title":"Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor","volume":"63","author":"Nishi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib32","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0105-17.2017","article-title":"Hippocampal TNFalpha signaling contributes to seizure generation in an infection-induced mouse model of limbic epilepsy","volume":"4","author":"Patel","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2022.109310_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/epi4.12351","article-title":"Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus","volume":"4","author":"Patel","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neuropharm.2022.109310_bib34","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","article-title":"The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors","volume":"33","author":"Paul","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109310_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1162\/jocn.1994.6.4.321","article-title":"Dissociation of motor hyperactivity and spatial memory deficits by selective hippocampal lesions in the neonatal rat","volume":"6","author":"Praag","year":"1994","journal-title":"J. Cognit. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109310_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13365-019-00740-3","article-title":"Microglial cell depletion is fatal with low level picornavirus infection of the central nervous system","volume":"25","author":"Sanchez","year":"2019","journal-title":"J. Neurovirol."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109310_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01748.x","article-title":"Central nervous system infections and epilepsy","volume":"49","author":"Singh","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106949","article-title":"The global burden of epilepsy report: implications for low- and middle-income countries","volume":"105","author":"Singh","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2022.109310_bib39","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/NEN.0b013e3181ffc420","article-title":"Development of postinfection epilepsy after Theiler's virus infection of C57BL\/6 mice","volume":"69","author":"Stewart","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109310_bib40","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1528-1167.2009.02405.x","article-title":"Theiler's virus infection chronically alters seizure susceptibility","volume":"51","author":"Stewart","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109310_bib41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nbd.2013.12.015","article-title":"Impaired cognitive ability and anxiety-like behavior following acute seizures in the Theiler's virus model of temporal lobe epilepsy","volume":"64","author":"Umpierre","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109310_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbr.2011.03.049","article-title":"Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease","volume":"222","author":"Walker","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109310_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbi.2018.09.006","article-title":"Microglia have a protective role in viral encephalitis-induced seizure development and hippocampal damage","volume":"74","author":"Waltl","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2022.109310_bib44","series-title":"Epilepsy Fact Sheet","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109310_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-94-017-8914-1_14","article-title":"Does brain inflammation mediate pathological outcomes in epilepsy?","volume":"813","author":"Wilcox","year":"2014","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:20:57Z","timestamp":1758439257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":45,"alternative-id":["S0028390822003690"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109310","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109310"}}